Don't miss this satellite symposium, designed to equip you with the latest insights in precision medicine for IgA nephropathy (IgAN). Through dynamic, case-based discussions led by leading nephrology experts, you’ll explore cutting-edge biomarkers, interpret updated clinical guidelines, and evaluate the safety and efficacy of both approved and emerging therapies. Whether you're looking to enhance diagnostic accuracy, tailor treatment strategies, or stay ahead of evolving standards of care, this symposium delivers practical, actionable knowledge you can apply directly to your clinical practice.
Precision Medicine in IgAN: A Deep Dive Into Biomarkers, Evolving Guidelines, and Therapeutic Frontiers
Join the experts in a case-based session on biomarker-guided diagnosis, evolving guideline updates, and emerging treatment strategies for IgAN.
Live
Meeting
Information
September 19, 2025
01:00 PM - 02:00 PM CEST
Cubex Centre Prague
Na Strži 2097/63 140 00 Prague 4, Room: A1, Prague, Czech Republic
Share
Share
Share
Share this program on:
Details
Presenters
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Co-Chair:
Chee Kay Cheung, MBChB, PhD, FRCP
Consultant Nephrologist
Honorary Associate Professor
University Hospitals of Leicester NHS Trust
Leicester, United Kingdom
Dr. Cheung has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Alexion, Alpine Immune Sciences, Boehringer Ingelheim, CSL Vifor, George Clinical, Novartis, Otsuka Pharmaceutical, Roche, Stada, Vertex
Research: Alexion, Alpine Immune Sciences, Kezar, Novartis, Otsuka Pharmaceutical, Travere Therapeutics, Vertex
Co-Chair:
Raphaël Duivenvoorden, MD
Associate Professor
Radboud University Medical Center
Nijmegen, The Netherlands
Dr. Duivenvoorden has no relevant relationships to disclose.
Reviewers/Content Planners/Authors:- Cindy Davidson has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
- Kathleen Sheridan, PhD, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Assess the role of biomarkers for diagnosing, predicting treatment response, and monitoring disease progression in IgAN
- Interpret the latest IgAN clinical practice guideline recommendations
- Evaluate the efficacy and safety of targeted approved and emerging IgAN therapies, as well as combination treatment strategies
Target Audience
This activity has been designed to meet the educational needs of nephrologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with immunoglobulin A nephropathy (IgAN).
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).
This live activity is accredited by the European Board for Accreditation of Continuing Education for Health Professional (EBAC®) for 60 minutes of effective education time.Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.Commercial Support
This activity is supported by an independent educational grant from CSL Vifor.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Details
Presenters
Overview
Don't miss this satellite symposium, designed to equip you with the latest insights in precision medicine for IgA nephropathy (IgAN). Through dynamic, case-based discussions led by leading nephrology experts, you’ll explore cutting-edge biomarkers, interpret updated clinical guidelines, and evaluate the safety and efficacy of both approved and emerging therapies. Whether you're looking to enhance diagnostic accuracy, tailor treatment strategies, or stay ahead of evolving standards of care, this symposium delivers practical, actionable knowledge you can apply directly to your clinical practice.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Co-Chair:
Chee Kay Cheung, MBChB, PhD, FRCP
Consultant Nephrologist
Honorary Associate Professor
University Hospitals of Leicester NHS Trust
Leicester, United Kingdom
Dr. Cheung has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Alexion, Alpine Immune Sciences, Boehringer Ingelheim, CSL Vifor, George Clinical, Novartis, Otsuka Pharmaceutical, Roche, Stada, Vertex
Research: Alexion, Alpine Immune Sciences, Kezar, Novartis, Otsuka Pharmaceutical, Travere Therapeutics, Vertex
Co-Chair:
Raphaël Duivenvoorden, MD
Associate Professor
Radboud University Medical Center
Nijmegen, The Netherlands
Dr. Duivenvoorden has no relevant relationships to disclose.
Reviewers/Content Planners/Authors:- Cindy Davidson has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
- Kathleen Sheridan, PhD, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Assess the role of biomarkers for diagnosing, predicting treatment response, and monitoring disease progression in IgAN
- Interpret the latest IgAN clinical practice guideline recommendations
- Evaluate the efficacy and safety of targeted approved and emerging IgAN therapies, as well as combination treatment strategies
Target Audience
This activity has been designed to meet the educational needs of nephrologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with immunoglobulin A nephropathy (IgAN).
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).This live activity is accredited by the European Board for Accreditation of Continuing Education for Health Professional (EBAC®) for 60 minutes of effective education time.Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.Commercial Support
This activity is supported by an independent educational grant from CSL Vifor.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Recommended
Managing Patients With AAV in the Rheumatology Clinic
Managing Patients With AAV in the Rheumatology Clinic
MinuteCE®Managing Patients With AAV in the Rheumatology Clinic
0.75 program credits
Andreas Kronbichler, MD
Bernhard Hellmich, MD
0.75 program creditsOptimizing AAV Outcomes: Maintenance Therapies
Optimizing AAV Outcomes: Maintenance Therapies
MinuteCE®Optimizing AAV Outcomes: Maintenance Therapies
0.75 program creditsBernhard Hellmich, MD
Silke R. Brix, MD, MRCP, SCPR
0.75 program creditsTailoring Treatment for Optimal Outcomes in Patients With AAV
Tailoring Treatment for Optimal Outcomes in Patients With AAV
MinuteCE®Tailoring Treatment for Optimal Outcomes in Patients With AAV
0.75 program creditsBernhard Hellmich, MD
Andreas Kronbichler, MD
0.75 program creditsElevating Care for Patients With Severe Renal Disease in AAV
Elevating Care for Patients With Severe Renal Disease in AAV
MinuteCE®Elevating Care for Patients With Severe Renal Disease in AAV
0.75 program creditsSilke R. Brix, MD, MRCP, SCPR
Andreas Kronbichler, MD
0.75 program credits